Bersacapavir

Bersacapavir (JNJ-6379) is a novel Hepatitis B Virus capsid assembly modulator. Bersacapavir interferes with the assembly process of the hepatitis B virus nucleocapsid by binding to the hydrophobic pocket at the dimer-dimer interface of hepatitis B core protein (HBc) subunits. Bersacapavir inhibits the replication of HBV. Bersacapavir is mainly used in the research of chronic hepatitis B[1][2][3].

Product Specifications

CAS Number

[1638266-40-6]

Product Name Alternative

JNJ-6379; JNJ-56136379

UNSPSC

12352005

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bersacapavir.html

Purity

99.24

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC(S(=O)(N[C@@H](C)C(F)(F)F)=O)=CN1C)NC2=CC=C(F)C(C#N)=C2

Molecular Formula

C16H14F4N4O3S

Molecular Weight

418.37

References & Citations

[1]Vandenbossche J, Jessner W, van den Boer M, Biewenga J, Berke JM, Talloen W, De Zwart L, Snoeys J, Yogaratnam J. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects. Adv Ther. 2019 Sep;36 (9) :2450-2462.|[2]Zheng Y, et al. Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein. Viruses. 2023 May 18;15 (5) :1195.|[3]Wooddell C I, et al. Discovery and Development of ARO‐HBV/JNJ‐3989. Trends in Antiviral Drug Development, 2025: 211-246.